(113 days)
The MicroScan® Dried Gram-Negative MIC/Combo Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-negative bacilli. After inoculation, panels are incubated for 16 - 20 hours at 35°C +/- 1°C in a non-CO2 incubator, and read either visually or with MicroScan instrumentation, according to the Package Insert.
This particular submission is for the addition of the antimicrobial Doripenem at concentrations of 0.008 to 32 mcg/ml to the test panel.
The gram-negative organisms which may be used for Doripenem susceptibility testing in this panel are:
Acinetobacter baumanii Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa
MicroScan Dried Gram-Negative MIC/Combo Panels are designed for use in determining quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-negative bacilli.
The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test that have been diluted in broth and dehydrated. Various antimicrobial agents are diluted in broth to concentrations bridging the range of clinical interest. Panels are rehydrated with water after inoculation with a standardized suspension of the organism. After incubation in a non-CO2 incubator for 16-20 hours, the minimum inhibitory concentration (MIC) for the test organism is read by determining the lowest antimicrobial concentration showing inhibition of growth.
The acceptance criteria related to the performance of the MicroScan Dried Gram-Negative MIC/Combo Panels with Doripenem, as described in the provided text, is primarily focused on Essential Agreement with a CLSI frozen Reference Panel.
Here's a breakdown of the requested information:
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria (Reference Panel Comparison) | Reported Device Performance (Doripenem) |
|---|---|
| Essential Agreement with CLSI frozen Reference Panel | 97.0% (Overall) |
| Reproducibility of Inoculum Method (Turbidity and Prompt™) | Acceptable |
| Reproducibility of Instrument (autoSCAN® -4 and WalkAway®) | Acceptable |
| Quality Control Testing for Doripenem | Acceptable |
Note: The document implicitly suggests that "acceptable" reproducibility and quality control are also part of the acceptance criteria, as their successful demonstration is highlighted.
2. Sample Size Used for the Test Set and the Data Provenance
- The document states: "The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains."
- It does not specify the exact total sample size for the test set (number of isolates or tests).
- The data provenance is not explicitly stated in terms of country of origin. Given Siemens Healthcare Diagnostics is the manufacturer and the FDA is the regulatory body, it is likely the study was conducted to meet US regulatory requirements, potentially using data gathered in the US or under US-standardized conditions.
- The study appears to be retrospective for the challenge strains (compared to "Expected Results determined prior to the evaluation"), and could be a mix for efficacy isolates (fresh isolates might involve prospective collection, while stock isolates are typically retrospective).
3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts
- The document does not provide any information on the number of experts used or their qualifications for establishing the ground truth.
4. Adjudication Method for the Test Set
- The document does not describe any adjudication method. It states that challenge strains were "compared to Expected Results determined prior to the evaluation," and the Dried Gram-Negative Panel's performance was compared with a CLSI frozen Reference panel. This suggests the reference panel results or pre-determined expected results served as the "ground truth" rather than an adjudicated expert consensus.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
- No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. This study is focused on the performance of the automated AST system (MicroScan panels) against a reference method, not on human readers' improvement with or without AI assistance. The device is for automated antimicrobial susceptibility testing, not assistive AI for human interpretation.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
- Yes, a standalone performance evaluation was done. The study directly compares the MicroScan Dried Gram-Negative MIC/Combo Panel's results to a CLSI frozen Reference panel. This is an evaluation of the device's (algorithm's) performance independent of human interpretation or intervention, except for initial setup and reading of the MICs, which can be automated (via autoSCAN® -4 and WalkAway® instruments) or visual.
7. The Type of Ground Truth Used
- The ground truth used was a CLSI frozen Reference Panel. For challenge strains, "Expected Results determined prior to the evaluation" also served as a form of ground truth. This is a standardized, recognized reference method for antimicrobial susceptibility testing.
8. The Sample Size for the Training Set
- The document does not provide any information about a separate training set or its sample size. The focus is on the performance of the device against a reference standard in an external evaluation. This is typical for AST device validations, where the system is "trained" during its development phase using various isolates, but the submission documentation primarily describes the validation (test set) performance.
9. How the Ground Truth for the Training Set Was Established
- As no information about a training set is provided, there is no information on how its ground truth was established.
{0}------------------------------------------------
X10/425 SEP 1 0 2010
510(k) Summary
510(k) Submission Information:
| Device Manufacturer: | Siemens Healthcare Diagnostics |
|---|---|
| Contact name: | Elisabeth Warriner, Regulatory Technical Specialist |
| Fax: | 916-374-3144 |
| Date prepared: | August 31, 2010 |
| Product Name: | Microdilution Minimum Inhibitory Concentration (MIC) Panels |
| Trade Name: | MicroScan Dried Gram-Negative MIC/Combo Panels |
| Intended Use: | To determine antimicrobial agent susceptibility |
| 510(k) Notification: | New antimicrobial - Doripenem |
| Predicate device: | MicroScan Dried Gram-Negative MIC/Combo Panels -Ertapenem (K032706) |
510(k) Summary:
MicroScan Dried Gram-Negative MIC/Combo Panels are designed for use in determining quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-negative bacilli.
The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test that have been diluted in broth and dehydrated. Various antimicrobial agents are diluted in broth to concentrations bridging the range of clinical interest. Panels are rehydrated with water after inoculation with a standardized suspension of the organism. After incubation in a non-CO2 incubator for 16-20 hours, the minimum inhibitory concentration (MIC) for the test organism is read by determining the lowest antimicrobial concentration showing inhibition of growth.
The proposed MicroScan Dried Gram-Negative MIC/Combo Panel demonstrated substantially equivalent performance when compared with an CLSI frozen Reference Panel, as defined in the FDA document "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA", dated August 28, 2009. The Premarket Notification (510[k]) presents data in support of the MicroScan Dried Gram-Negative MIC/Combo Panel with Doripenem.
The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains. The external evaluations were designed to confirm the acceptability of the proposed Dried Gram-Negative Panel by comparing its performance with a CLSI frozen Reference panel. Challenge strains were compared to Expected Results determined prior to the evaluation. The Dried Gram-Negative Panel demonstrated acceptable performance with an overall Essential Agreement of 97.0% for Doripenem when compared with the frozen Reference panel.
Inoculum and instrument reproducibility testing demonstrated acceptable reproducibility and precision with Doripenem, regardless of which inoculum method (i.e., Turbidity and Prompt™), or instrument (autoSCAN® -4 and WalkAway®) was used.
Quality Control testing demonstrated acceptable results for Doripenem.
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows the logo for the Department of Health & Human Services USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an abstract image of an eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002
Siemens Healthcare Diagnostics Inc. c/o Ms. Eliabeth Warriner Regulatory Technical Specialist 1584 Enterprise Blvd. West Sacramento, CA 95691
SEP 1 0 2010
Re: K101425
Trade/Device Name: MicroScan Dried Gram-Negative MIC/Combo Panels with Doripenem (0.008-32ug/mL)
Regulation Number: 21 CFR 866.1640 ·
Regulation Name: Antimicrobial Susceptibility Test Powder
Regulatory Class: Class II
Product Code: LRG, JWY, LTT Dated: September 9, 2010
Received: September 10, 2010
Dear Ms. Warriner:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish farther announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
{2}------------------------------------------------
Page 2 - Ms. Eliabeth Warriner
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Valgastin
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Indications for Use
SEP 1 0 2010
510(k) Number (if known): K. 10/425
Device Name: MicroScan® Dried Gram-Negative MIC/Combo Panels with Doripenem (0.008 -32 mcg/ml)
Indications For Use:
The MicroScan® Dried Gram-Negative MIC/Combo Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-negative bacilli. After inoculation, panels are incubated for 16 - 20 hours at 35°C +/- 1°C in a non-CO2 incubator, and read either visually or with MicroScan instrumentation, according to the Package Insert.
This particular submission is for the addition of the antimicrobial Doripenem at concentrations of 0.008 to 32 mcg/ml to the test panel.
The gram-negative organisms which may be used for Doripenem susceptibility testing in this panel are:
Acinetobacter baumanii Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Freddie Rie. Poole
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K101425
Page 1 of 1
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).